Factor II Follow-up

  • Author: Robert A Schwartz, MD, MPH; Chief Editor: Emmanuel C Besa, MD   more...
 
Updated: Feb 2, 2011
 

Prognosis

  • The prognosis of a patient with factor II deficiency depends on the etiology and severity of his or her disease. Although acquired factor II deficiency may be eliminated if the underlying cause is treated, the congenital form of the disease is lifelong. Despite the fact that specific levels of factor II and severity of symptoms are poorly correlated, patients with very low levels of functional factor II have a greater tendency to hemorrhage and thus face a greater risk of life-threatening complications.
Next

Patient Education

Previous
 
Contributor Information and Disclosures
Author

Robert A Schwartz, MD, MPH  Professor and Head, Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, University of Medicine and Dentistry of New Jersey-New Jersey Medical School

Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and Sigma Xi

Disclosure: Nothing to disclose.

Coauthor(s)

Christopher J Steen, MD  Dermatologist, Private Practice

Christopher J Steen, MD is a member of the following medical societies: Alpha Omega Alpha and Sigma Xi

Disclosure: Nothing to disclose.

Pere Gascon, MD, PhD  Professor and Director, Division of Medical Oncology, Institute of Hematology and Medical Oncology, IDIBAPS, University of Barcelona Faculty of Medicine, Spain

Pere Gascon, MD, PhD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, New York Academy of Medicine, New York Academy of Sciences, and Sigma Xi

Disclosure: Nothing to disclose.

Specialty Editor Board

Paul Schick, MD  Emeritus Professor, Department of Internal Medicine, Jefferson Medical College of Thomas Jefferson University; Research Professor, Department of Internal Medicine, Drexel University College of Medicine; Adjunct Professor of Medicine, Lankenau Hospital

Paul Schick, MD is a member of the following medical societies: American College of Physicians, American Heart Association, American Society of Hematology, International Society on Thrombosis and Haemostasis, and New York Academy of Sciences

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Ronald A Sacher, MB, BCh, MD, FRCPC  Professor, Internal Medicine and Pathology, Director, Hoxworth Blood Center, University of Cincinnati Academic Health Center

Ronald A Sacher, MB, BCh, MD, FRCPC is a member of the following medical societies: American Association for the Advancement of Science, American Association of Blood Banks, American Clinical and Climatological Association, American Society for Clinical Pathology, American Society of Hematology, College of American Pathologists, International Society of Blood Transfusion, International Society on Thrombosis and Haemostasis, and Royal College of Physicians and Surgeons of Canada

Disclosure: Glaxo Smith Kline Honoraria Speaking and teaching; Talecris Honoraria Board membership

Rebecca J Schmidt, DO, FACP, FASN  Professor of Medicine, Section Chief, Department of Medicine, Section of Nephrology, West Virginia University School of Medicine

Rebecca J Schmidt, DO, FACP, FASN is a member of the following medical societies: American College of Physicians, American Medical Association, American Society of Nephrology, International Society of Nephrology, National Kidney Foundation, Renal Physicians Association, and West Virginia State Medical Association

Disclosure: Renal Ventures Ownership interest Other

Chief Editor

Emmanuel C Besa, MD  Professor, Department of Medicine, Division of Hematologic Malignancies, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University

Emmanuel C Besa, MD is a member of the following medical societies: American Association for Cancer Education, American College of Clinical Pharmacology, American Federation for Medical Research, American Society of Clinical Oncology, American Society of Hematology, and New York Academy of Sciences

Disclosure: Nothing to disclose.

References

  1. Quick AJ. Congenital hypoprothrombinemia and pseudo-hypoprothrombinemia. Lancet. 1947;ii:379-82.

  2. Shapiro SS, Martinez J, Holburn RR. Congenital dysprothrombinemia: an inherited structural disorder of human prothrombin. J Clin Invest. Dec 1969;48(12):2251-9. [Medline]. [Full Text].

  3. Baudo F, de Cataldo F, Josso F, Silvello L. Hereditary hypoprothrombinaemia. True deficiency of factor II. Acta Haematol. 1972;47(4):243-9. [Medline].

  4. Girolami A, Scarano L, Saggiorato G, et al. Congenital deficiencies and abnormalities of prothrombin. Blood Coagul Fibrinolysis. Oct 1998;9(7):557-69. [Medline].

  5. Bajaj SP, Rapaport SI, Barclay S, Herbst KD. Acquired hypoprothrombinemia due to non-neutralizing antibodies to prothrombin: mechanism and management. Blood. Jun 1985;65(6):1538-43. [Medline]. [Full Text].

  6. Royle NJ, Irwin DM, Koschinsky ML, MacGillivray RT, Hamerton JL. Human genes encoding prothrombin and ceruloplasmin map to 11p11-q12 and 3q21-24, respectively. Somat Cell Mol Genet. May 1987;13(3):285-92. [Medline].

  7. Degen SJ. The prothrombin gene and its liver-specific expression. Semin Thromb Hemost. 1992;18(2):230-42. [Medline].

  8. Sun WY, Witte DP, Degen JL, Colbert MC, Burkart MC, Holmbäck K, et al. Prothrombin deficiency results in embryonic and neonatal lethality in mice. Proc Natl Acad Sci U S A. Jun 23 1998;95(13):7597-602. [Medline]. [Full Text].

  9. Sun WY, Coleman MJ, Witte DP, Degen SJ. Rescue of prothrombin-deficiency by transgene expression in mice. Thromb Haemost. Dec 2002;88(6):984-91. [Medline].

  10. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. Nov 15 1996;88(10):3698-703. [Medline]. [Full Text].

  11. Pollak ES, Lam HS, Russell JE. The G20210A mutation does not affect the stability of prothrombin mRNA in vivo. Blood. Jul 1 2002;100(1):359-62. [Medline]. [Full Text].

  12. Ceelie H, Spaargaren-van Riel CC, Bertina RM, Vos HL. G20210A is a functional mutation in the prothrombin gene; effect on protein levels and 3'-end formation. J Thromb Haemost. Jan 2004;2(1):119-27. [Medline].

  13. Rosendaal FR, Doggen CJ, Zivelin A, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost. Apr 1998;79(4):706-8. [Medline].

  14. Atasay B, Arsan S, Gunlemez A, Kemahli S, Akar N. Factor V Leiden and prothrombin gene 20210A variant in neonatal thromboembolism and in healthy neonates and adults: a study in a single center. Pediatr Hematol Oncol. Dec 2003;20(8):627-34. [Medline].

  15. Irdem A, Devecioglu C, Batun S, Soker M, Sucakli IA. Prevalence of factor V Leiden and prothrombin G20210A gene mutation. Saudi Med J. Apr 2005;26(4):580-3. [Medline].

  16. Margaglione M, Brancaccio V, Giuliani N, et al. Increased risk for venous thrombosis in carriers of the prothrombin G-->A20210 gene variant. Ann Intern Med. Jul 15 1998;129(2):89-93. [Medline]. [Full Text].

  17. Lalouschek W, Schillinger M, Hsieh K, et al. Matched case-control study on factor V Leiden and the prothrombin G20210A mutation in patients with ischemic stroke/transient ischemic attack up to the age of 60 years. Stroke. Jul 2005;36(7):1405-9. [Medline]. [Full Text].

  18. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. Feb 9 2005;293(6):715-22. [Medline]. [Full Text].

  19. Cugno M, Marzano AV, Asero R, Tedeschi A. Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications. Intern Emerg Med. Apr 2010;5(2):97-101. [Medline].

  20. Kawakami T. New algorithm (KAWAKAMI algorithm) to diagnose primary cutaneous vasculitis. J Dermatol. Feb 2010;37(2):113-24. [Medline].

  21. Tabata N, Oonami K, Ishibashi M, Yamazaki M. Livedo vasculopathy associated with IgM anti-phosphatidylserine-prothrombin complex antibody. Acta Derm Venereol. May 2010;90(3):313-4. [Medline].

  22. Narayanan S. Multifunctional roles of thrombin. Ann Clin Lab Sci. Oct-Dec 1999;29(4):275-80. [Medline].

  23. Zhou H, Gabazza EC, Takeya H, et al. Prothrombin and its derivatives stimulate motility of melanoma cells. Thromb Haemost. Sep 1998;80(3):407-12. [Medline].

  24. Akhavan S, Mannucci PM, Lak M, et al. Identification and three-dimensional structural analysis of nine novel mutations in patients with prothrombin deficiency. Thromb Haemost. Dec 2000;84(6):989-97. [Medline].

  25. Sun WY, Ruiz-Saez A, Burkart MC, Bosch N, Degen SJ. Prothrombin carora: hypoprothrombinaemia caused by substitution of Tyr-44 by Cys. Br J Haematol. Jun 1999;105(3):670-2. [Medline].

  26. Wang W, Fu Q, Zhou R, et al. Prothrombin Shanghai: hypoprothrombinaemia caused by substitution of Gla29 by Gly. Haemophilia. Jan 2004;10(1):94-7. [Medline].

  27. Jayandharan G, Viswabandya A, Baidya S, et al. Molecular genetics of hereditary prothrombin deficiency in Indian patients: identification of a novel Ala362 --> Thr (Prothrombin Vellore 1) mutation. J Thromb Haemost. Jul 2005;3(7):1446-53. [Medline]. [Full Text].

  28. Sun WY, Smirnow D, Jenkins ML, Degen SJ. Prothrombin Scranton: substitution of an amino acid residue involved in the binding of Na+ (LYS-556 to THR) leads to dysprothrombinemia. Thromb Haemost. Apr 2001;85(4):651-4. [Medline].

  29. Lefkowitz JB, Weller A, Nuss R, et al. A common mutation, Arg457-->Gln, links prothrombin deficiencies in the Puerto Rican population. J Thromb Haemost. Nov 2003;1(11):2381-8. [Medline].

  30. Kling SJ, Jones KA, Rodgers GM. A second case of prothrombin Puerto Rico I in the United States. Am J Hematol. Jul 2007;82(7):661-2. [Medline]. [Full Text].

  31. Rouy S, Vidaud D, Alessandri JL, et al. Prothrombin Saint-Denis: a natural variant with a point mutation resulting in Asp to Glu substitution at position 552 in prothrombin. Br J Haematol. Mar 2006;132(6):770-3. [Medline].

  32. Bhat RV, Deshmukh CT. A study of Vitamin K status in children on prolonged antibiotic therapy. Indian Pediatr. Jan 2003;40(1):36-40. [Medline]. [Full Text].

  33. Baudo F, Redaelli R, Pezzetti L, et al. Prothrombin-antibody coexistent with lupus anticoagulant (LA): clinical study and immunochemical characterization. Thromb Res. Jan 15 1990;57(2):279-87. [Medline].

  34. Taddio A, Brescia AC, Lepore L, Rose CD. Steady improvement of prothrombin levels after cyclophosphamide therapy in pediatric lupus anticoagulant hypoprothrombinemia syndrome (LAHPS). Clin Rheumatol. Dec 2007;26(12):2167-9. [Medline].

  35. Cote HC, Huntsman DG, Wu J, Wadsworth LD, MacGillivray RT. A new method for characterization and epitope determination of a lupus anticoagulant-associated neutralizing antiprothrombin antibody. Am J Clin Pathol. Feb 1997;107(2):197-205. [Medline].

  36. Vivaldi P, Rossetti G, Galli M, Finazzi G. Severe bleeding due to acquired hypoprothrombinemia-lupus anticoagulant syndrome. Case report and review of literature. Haematologica. May-Jun 1997;82(3):345-7. [Medline]. [Full Text].

  37. Degen S. Prothrombin. In: High K, Roberts H, eds. Molecular Basis of Thrombosis and Hemostasis. New York, NY: Marcel Dekker; 1995:75.

  38. Lechler E. Use of prothrombin complex concentrates for prophylaxis and treatment of bleeding episodes in patients with hereditary deficiency of prothrombin, factor VII, factor X, protein C protein S, or protein Z. Thromb Res. Aug 15 1999;95(4 suppl 1):S39-50. [Medline].

  39. Akhavan S, Luciani M, Lavoretano S, Mannucci PM. Phenotypic and genetic analysis of a compound heterozygote for dys- and hypoprothrombinaemia. Br J Haematol. Jan 2003;120(1):142-4. [Medline].

  40. Girolami A, Scarparo P, Allemand E. Mutations are no substitutes for clotting, chromogenic and immunological assays in patients with congenital prothrombin deficiency. Am J Hematol. Jun 2008;83(6):518; author reply 518-9. [Medline].

  41. HEMEX Laboratories. 'II' be or not 'II' be tested. Prothrombin gene mutation - a new thrombophilia risk. Updated January 23, 2003. Accessed December 2, 2008. [Full Text].

  42. Henriksen RA, Dunham CK, Miller LD, et al. Prothrombin Greenville, Arg517-->Gln, identified in an individual heterozygous for dysprothrombinemia. Blood. Mar 15 1998;91(6):2026-31. [Medline]. [Full Text].

  43. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. Mar 25 1999;340(12):901-7. [Medline]. [Full Text].

  44. Kearon C, Julian JA, Kovacs MJ, et al. Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood. Dec 1 2008;112(12):4432-6. [Medline].

  45. McMahon MJ, James AH. Combined deficiency of factors II, VII, IX, and X (Borgschulte-Grigsby deficiency) in pregnancy. Obstet Gynecol. May 2001;97(5 pt 2):808-9. [Medline].

  46. Medline Plus Medical Encyclopedia. Factor II deficiency. Updated March 13, 2007. Available at http://www.nlm.nih.gov/medlineplus/ency/article/000549.htm. Accessed December 2, 2008.

  47. National Hemophilia Foundation. Learn about coagulation disorders: factor II deficiency. Available at http://www.hemophilia.org/bdi/bdi_types5.htm. Accessed December 2, 2008.

  48. Rossi E, Za T, Ciminello A, Leone G, De Stefano V. The risk of symptomatic pulmonary embolism due to proximal deep venous thrombosis differs in patients with different types of inherited thrombophilia. Thromb Haemost. Jun 2008;99(6):1030-4. [Medline].

  49. Strijks E, Poort SR, Renier WO, Gabreels FJ, Bertina RM. Hereditary prothrombin deficiency presenting as intracranial haematoma in infancy. Neuropediatrics. Dec 1999;30(6):320-4. [Medline].

  50. Sun WY, Burkart MC, Holahan JR, Degen SJ. Prothrombin San Antonio: a single amino acid substitution at a factor Xa activation site (Arg320 to His) results in dysprothrombinemia. Blood. Jan 15 2000;95(2):711-4. [Medline]. [Full Text].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.